Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (Addl1520) for treatment of liver tumors

被引:71
作者
Hong, SS
Habib, NA
Franqueville, L
Jensen, S
Boulanger, PA
机构
[1] RTH Laennec, Lab Virol & Pathogenese Virale, UMR 5537, Fac Med,CNRS, F-69372 Lyon, France
[2] RTH Laennec, Inst Federatif Rech, F-69372 Lyon, France
[3] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Surg Oncol & Technol, London W12 0NN, England
关键词
D O I
10.1128/JVI.77.19.10366-10375.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Sera from 17 patients with primary and secondary liver tumors who had been administered oncolytic adenovirus (Ad) mutant Addl1520 were analyzed for anti-Ad neutralization titers and antibodies to the Ad major capsid proteins hexon, penton base (Pb), and fiber. The antibodies recognized mainly conformational epitopes in hexon and both linear and conformational epitopes in Pb and fiber. Pb-specific antibodies were isolated from serum samples that had been obtained prior to and during the course of the treatment of four of these patients. We found that the Pb antibodies had a significant contribution toward anti-Ad neutralization, and this mainly occurred at the step of virus internalization. The Pb antigenic epitopes were determined by phage biopanning and were mapped to 10 discrete regions, which made up three major immunodominant domains within residues 51 to 120, 193 to 230, and 311 to 408, respectively. One of these domains (residues 311 to 408) overlapped the highly conserved, integrin-binding RGD (Arg-Gly-Asp) motif. The contribution of antibodies directed to RGD and other epitopes in Ad neutralization activity was determined indirectly by using a phage-mediated depletion assay. Our results suggested that circulating RGD antibodies were not prevalent and were poorly neutralizing and that other peptide motifs within residues 51 to 60, 216 to 226, and 311 to 408 in Pb sequence represented major target sites for neutralizing antibodies.
引用
收藏
页码:10366 / 10375
页数:10
相关论文
共 36 条
[1]   ADENOVIRUS PROTEINS FROM BOTH E1B READING FRAMES ARE REQUIRED FOR TRANSFORMATION OF RODENT CELLS BY VIRAL-INFECTION AND DNA TRANSFECTION [J].
BARKER, DD ;
BERK, AJ .
VIROLOGY, 1987, 156 (01) :107-121
[2]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[3]   LARGE-SCALE PREPARATION OF SOLUBLE ADENOVIRUS HEXON, PENTON AND FIBER ANTIGENS IN HIGHLY PURIFIED FORM [J].
BOULANGE.PA ;
PUVION, F .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1973, 39 (01) :37-42
[4]   Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy [J].
Chen, Y ;
Yu, DC ;
Charlton, D ;
Henderson, DR .
HUMAN GENE THERAPY, 2000, 11 (11) :1553-1567
[5]   Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues [J].
CrawfordMiksza, L ;
Schnurr, DP .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1836-1844
[6]   ANTIGENIC SITES ON THE RECEPTOR-BINDING DOMAIN OF HUMAN ADENOVIRUS TYPE-2 FIBER [J].
FENDER, P ;
KIDD, AH ;
BREBANT, R ;
OBERG, M ;
DROUET, E ;
CHROBOCZEK, J .
VIROLOGY, 1995, 214 (01) :110-117
[7]  
Gahéry-Ségard H, 1998, J VIROL, V72, P2388
[8]  
Ganly I, 2000, CLIN CANCER RES, V6, P798
[9]   Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma [J].
Habib, N ;
Salama, H ;
Abu Median, AAEL ;
Anis, II ;
Al Aziz, RAA ;
Sarraf, C ;
Mitry, R ;
Havlik, R ;
Seth, P ;
Hartwigsen, J ;
Bhushan, R ;
Nicholls, J ;
Jensen, S .
CANCER GENE THERAPY, 2002, 9 (03) :254-259
[10]   E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors [J].
Habib, NA ;
Sarraf, CE ;
Mitry, RR ;
Havlík, R ;
Nicholls, J ;
Kelly, M ;
Vernon, GC ;
Gueret-Wardle, D ;
El-Masry, R ;
Salama, H ;
Ahmed, R ;
Michail, N ;
Edward, E ;
Jensen, SL .
HUMAN GENE THERAPY, 2001, 12 (03) :219-226